Integumen is a vertically integrated business. It’s core skin and human testing technology is built on a clinical based eco-system. Collaboration partners in artificial intelligence, clinical research, medical device and life science contribute to the service management platform. This allows skin-care, health-care, nutritional, pharmaceutical manufacturers and cosmetic companies to test consumer products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company’s own skin-care range of products and cannabinoid oils (CBD) sources have been used to test the platform that combines data analytics with access to therapeutic operational expertise offering client solutions ranging from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our laboratory grown living human tissue (Labskin).
Country of Incorporation
Integumen plc is incorporated in England and Wales with Registration Number 10205396. Integumen plc has operations in Ireland and the UK, and its main country of operation is the UK.
Sand Hutton Applied Innovation Campus
Sand Hutton, York
North Yorkshire YO41 1LZ
19 Railway Road
Dalkey, Co. Dublin
Articles of Association
The Company’s Articles of Association can be downloaded here
Management and Board
Board of Directors
Ross Andrews, Non-Executive Chairman Ross is a highly experienced corporate adviser with 30 years’ experience advising companies and management teams on public market transactions, largely in the UK but also in Europe, Australia, and Asia. He has worked with large corporates as well as numerous small, growing companies, providing advice on a range of equity capital matters, including IPOs, fundraisings, strategy, acquisitions, corporate governance and shareholder matters. Ross was a director and shareholder of Zeus Capital Limited until July 2015 when he formed RMA Consultancy Limited to undertake non-executive appointments or consultancy and project management roles within companies undergoing management change, external investment rounds or seeking a liquidity event through IPO or other exits.
Gerard Brandon, Chief Executive Officer Gerard was appointed Director and CEO of Integumen in August 2018. Previously, he joined Cellulac Limited (Ireland) as its Chief Executive Officer in May 2012 and assumed the same role for Cellulac plc in October 2013. In 1996 he became founder and CEO of Alltracel Pharmaceuticals PLC, where he built a team that oversaw numerous patents granted on refined cellulose. Alltracel was admitted to trading on AIM in 2001. In 2004, he was appointed as a Managing Partner for Farmabrand Private Equity. In 2009, he was appointed as an Executive Consultant to Eplixo Limited. He is a Fellow of the Ryan Academy of Entrepreneurs in Dublin.
Camillus Glover, Chief of Finance and Operations Camillus was appointed Director and COO of Integumen in August 2018. on the 29th of August he took over as Chief Financial Officer. Previously, he joined Cellulac Limited (Ireland) as Chief Financial Officer in May 2012 and assumed the same role for Cellulac plc in October 2013. He is a member of the Institute of Chartered Accountants Ireland. In 2003, he joined Alltracel as Commercial Director and was appointed Chief Operations Officer in 2005 until it was acquired in 2008 by Hemcon Medical Technologies (“Hemcon”). Between 2009 and 2012, he was VP of Global Business Development for Hemcon prior to joining Cellulac.
Fionan (Fin) Murray, Group Sales Director Fin is the Founder of Rinocloud Limited. He is a seasoned sales executive with more than 30 years’ experience in worldwide distribution deals, selling complex software solutions into the multi-national corporate sectors in financial services, biotech, utilities and government departments. He is former CEO of LeT Systems Ltd and a senior executive at KBC Bank and Kindle Banking systems.
Securities in Issue
As at 14 October 2019, the number of securities in issue was 981,163,373
As at 14 October 2019, shareholders holding more than 3% of the share capital of Integumen were:
|Shareholder Name||No. of Ordinary Shares||% of Existing Share Capital|
|Helium Rising Stars||72,333,723||7.38%|
Note: Gerard Brandon and Camillus Glover are directors of Cellulac.
Shares not in public hands
transfer of securities
There are no restrictions on the transfer of Integumen’s securities
Other exchanges and trading platforms
Integumen plc has not applied or agreed to have its securities admitted or traded on any other exchanges or trading platforms
UK City Code on Takeovers and Mergers
Integumen plc is subject to the UK City Code on Takeovers and Mergers legislation
Page last updated 14 October 2019
Share Dealing Code
The Company will take proper steps to ensure compliance by the Directors and applicable employees with the terms of the share dealing code and the relevant provisions of the AIM Rules for Companies (including Rule 21).
Reports & Accounts
Integumen PLC Interim Report 2019 – download pdf version.
Integumen PLC Annual Report 2018 – download pdf version.
Integumen PLC Interim Report 2018 – download pdf version.
Integumen PLC Annual Report 2017 – download pdf version.
Integumen PLC Interim Report 2017 – download pdf version.
Integumen PLC Annual Report 2016 – download pdf version.
Circulars & Notices
AGM Circular & Proxy August 2019 – download pdf version.
EGM Circular & Proxy April 2019 – download pdf version.
EGM Circular & Proxy November 2018 – download pdf version.
AGM Circular & Proxy August 2018 – download pdf version.
EGM Circular & Proxy July 2018 – download pdf version.
EGM Circular & Proxy 2017 – download pdf version.
The Company’s Admission Document can be downloaded here.
Articles of Association
The Company’s Articles of Association can be downloaded here.
AIM Rule 26
AIM Rule 26
The following information is disclosed for the purposes of compliance with AIM Rule 26. This information was last updated on 5 April 2017.
Description of the business see Company Information
Names of the Directors and biographical details see Board of Directors
Responsibilities of the Directors see Corporate Governance
Country of incorporation/operation see Company Information
Current Constitutional documents see Company Documents
Shareholder Information see Shareholder Information
- Number of securities in issue
- Significant shareholders
- Shares not in public hands
- Restrictions on transfer of securities
- Other exchanges and trading platforms
- UK City Code on Takeovers and Mergers
Corporate governance code see Corporate Governance
Company announcements made in the past 12 months see Regulatory News Service (RNS)
Financial Information see Reports and Accounts
Admission document and circulars see Company Documents
Advisers see Advisers
|Spark Advisory Partners Limited|
5 St John's Lane
London EC1M 4BH
|Turner Pope Investments Limited
6th Floor – Becket House
36 Old Jewry
Neville Registrars Limited
18 Laurel Lane
Halesowen B63 3DA
|Solicitors to the Nominated Advisor
Addleshaw Goddard LLP
60 Chiswell Street
London EC1Y 4AG
Jeffreys Henry LLP
Finsgate 5-7 Cranwood Street
London EC1V 9EE
|Solicitors to Integumen
BPE Solicitors LLP
St James House
St James Square
Cheltenham GL50 3PR
Turner Pope Company Update 7 Oct 2019 – Download PDF version.
Turner Pope Interim Report 11 Sept 2019 – Download PDF version.
Turner Pope Note 5 Sept 2019 – Download PDF version.
Turner Pope Note 29 July 2019 – Download PDF version.
Turner Pope Note 19 July 2019 – Download PDF version.
Turner Pope Note 8 July 2019 – Download PDF version.
Turner Pope Note 29 April 2019 – Download PDF version.
Labskin enters clinical trials space
Completion of artificial intelligence acquisition
Investor Event May 13 2019
Watch from 16:34 minutes in
Watch from 17 minutes in
Have an Investor Question?
Email us anytime
Or call — +44 (20) 3239 3716